IL2 and vasculitis: Generally, low-dose IL-2 therapy was very well tolerated, and progressively induced an expansion of Tregs with potent suppressive activity, leading to achievement of the pre-specified absolute 4% increment as the end point in as many as 80% of the HCV-related vasculitis patients at the fourth treatment course.